Carnot institutes

CEA LETI & CEA LIST participate in the Consumer Electronic Show (CES) with three spin-off start-ups

For this 100% digital version, the CEA is supporting 3 spin off start-ups from its laboratories that have developed technological solutions in response to three major societal challenges: 

  • The energy transition, with Wise-Integration, which will present the world's smallest charger for electric bicycles,

  • The digital transition with Alkalee, which has developed a software suite equipped to bring agility and openness to the vehicles of tomorrow,

  • And the health of the future, with iUMTEK for rapid quantitative and qualitative diagnosis of air pollution

Institut Curie (Curie Cancer Carnot Institute) & Google initiate a collaboration using artificial intelligence (AI) for the analysis of complex data

Institut Curie (Curie Cancer Carnot Institute) and Google initiate a joint artificial intelligence research program to develop and implement deep learning methods for the analysis of complex single-cell transcriptomic and epigenetics data. Obtained from mouse samples and cell lines, these valuable data sets will be used to develop new deep-learning algorithms. In the long term, this research project could help characterize the heterogeneity of tumors and predict resistance to treatment.

Ibex Medical Analytics & Institut Curie (Curie Cancer Carnot Institute) partner to improve AI-powered breast cancer detection

Institut Curie (Curie Cancer Carnot Insitute) and Ibex Medical Analytics, a pioneer in artificial intelligence based cancer diagnostics, announce a research partnership aimed at improving diagnosis of breast cancer with Artificial Intelligence

Owkin and CALYM Carnot Institute Launch a Collaboration to Advance Lymphoma Research with Artificial Intelligence

Owkin, a startup that deploys AI and Federated Learning technologies to augment medical research and enable scientific discoveries, announces a collaboration with Lymphoma research consortium Institut Carnot CALYM. This engagement was formed to leverage high-quality datasets from LYSARC, member of Institut Carnot CALYM, as well as Owkin’s pioneering technologies and research platform, to advance clinical research and drug development for the benefit of patients.